HDAC9 and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Exposure of mdx mice to HDAC inhibitors demonstrated therapeutic effects in dystrophinopathy, including histological improvement in fibrosis and inflammation, as well as enhanced muscle regeneration, decreased membrane permeability, and increased muscle strength and performance (Mozzetta et al., 2024).